RxDoctor Payments Data

Rachel Williams, MD

Family Medicine · Big Rapids, MINPI 1598849796

Payments from drug & device makers

$918in general payments, 2019–2025

Across 39 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$200
  • AstraZeneca$182
  • AbbVie$169
  • Kerecis Limited$147
  • Smith+Nephew$60
  • Novo Nordisk$37
  • plus $123 from 5 others

What the payments were for

  • Food & beverage$918100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$918 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$117,470
Medicare patients
164
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$53,815
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$36,627
TrulicityDulaglutide28$31,243
MounjaroTirzepatide15$15,696
JardianceEmpagliflozin13$13,518
SymbicortBudesonide/Formoterol Fumarate30$9,046
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$5,144
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$5,025
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$4,809
Atorvastatin Calcium212$4,196
Albuterol Sulfate HfaAlbuterol Sulfate115$3,795
Levothyroxine Sodium237$3,016
Omeprazole126$2,426
Duloxetine Hcl86$2,288
Rosuvastatin Calcium100$2,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$19$46,93843 claims
GSKTrelegy Ellipta$30$36,62737 claims
AstraZenecaSymbicort$182$9,04630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Big Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →